LARGUE PHARMACY LIMITED

Company Registration Number:
SC257732 (Scotland)

Unaudited abridged accounts for the year ended 31 August 2024

Period of accounts

Start date: 01 September 2023

End date: 31 August 2024

LARGUE PHARMACY LIMITED

Contents of the Financial Statements

for the Period Ended 31 August 2024

Balance sheet
Notes

LARGUE PHARMACY LIMITED

Balance sheet

As at 31 August 2024


Notes

2024

2023


£

£
Called up share capital not paid: 0 0
Fixed assets
Intangible assets: 3 246,000 287,000
Tangible assets: 4 251,422 269,640
Investments:   0 0
Total fixed assets: 497,422 556,640
Current assets
Stocks: 184,252 181,581
Debtors:   231,245 195,801
Cash at bank and in hand: 578,328 565,169
Investments:   0 0
Total current assets: 993,825 942,551
Creditors: amounts falling due within one year:   (425,289) (400,977)
Net current assets (liabilities): 568,536 541,574
Total assets less current liabilities: 1,065,958 1,098,214
Creditors: amounts falling due after more than one year:   0 0
Provision for liabilities: (58,942) (24,921)
Total net assets (liabilities): 1,007,016 1,073,293
Capital and reserves
Called up share capital: 1,250 1,250
Share premium account: 0 0
Revaluation reserve: 00
Other reserves: 0 0
Profit and loss account: 1,005,766 1,072,043
Shareholders funds: 1,007,016 1,073,293

The notes form part of these financial statements

LARGUE PHARMACY LIMITED

Balance sheet statements

For the year ending 31 August 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 12 December 2024
and signed on behalf of the board by:

Name: G A Largue
Status: Director

The notes form part of these financial statements

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2024

2. Employees

2024 2023
Average number of employees during the period 24 21

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2024

3. Intangible Assets

Total
Cost £
At 01 September 2023 1,250,000
Additions 0
Disposals 0
Revaluations 0
Transfers 0
At 31 August 2024 1,250,000
Amortisation
At 01 September 2023 963,000
Charge for year 41,000
On disposals 0
Other adjustments 0
At 31 August 2024 1,004,000
Net book value
At 31 August 2024 246,000
At 31 August 2023 287,000

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2024

4. Tangible Assets

Total
Cost £
At 01 September 2023 602,078
Additions 10,900
Disposals 0
Revaluations 0
Transfers 0
At 31 August 2024 612,978
Depreciation
At 01 September 2023 332,438
Charge for year 29,118
On disposals 0
Other adjustments 0
At 31 August 2024 361,556
Net book value
At 31 August 2024 251,422
At 31 August 2023 269,640